Medicare Advantage insurers and their distribution partners are bracing for a busy Annual Election Period, thanks in part to multiple Part D benefit changes resulting from the Inflation Reduction Act. Adding to their concerns about likely market disruption and enrollee confusion is a new drug manufacturer letter that raises operational and financial questions about the interplay between Patient Assistance Programs (PAPs) and the Medicare Payment Prescription Plan (M3P).
Key Takeaways
-
Pfizer notified Medicare Part D enrollees participating in its oncology drug patient assistance program that they to re-enroll in 2025, they must attest they have enrolled...
In a letter dated 19 August, Pfizer informed Part D beneficiaries using its Pfizer Oncology Together program that they must enroll in the M3P, which allows beneficiaries to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?